Efficiency of HPV 16 L1/E7 DNA immunization: Influence of cellular localization and capsid assembly

Vaccine

Volumn 24, Issue 15, 2006, Pages 2952-2965

  Kuck, Dirk ^a   Leder, Christoph ^a,b   Kern, Andrea ^a   Müller, Martin ^a   Piuko, Konrad ^a   Gissmann, Lutz ^a   Kleinschmidt, Jürgen A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DNA immunization; Papillomavirus

Indexed keywords

CALGRANULIN; CAPSID PROTEIN; DNA VACCINE; PROTEIN E7; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GENE DELETION; GENE EXPRESSION; HELA CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OUTCOME ASSESSMENT; PLASMID VECTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VIRUS CAPSID; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, VIRAL; CAPSID; CAPSID PROTEINS; CELL NUCLEUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED C57BL; NUCLEAR LOCALIZATION SIGNALS; ONCOGENE PROTEINS, VIRAL; PROTEIN STRUCTURE, TERTIARY; SEQUENCE DELETION; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 33644880219     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.12.023     Document Type: Article

References (56)

1. M. Durst, L. Gissmann, H. Ikenberg, and H. zur Hausen A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions Proc Natl Acad Sci USA 80 12 1983 3812 3815
2. K. Seedorf, G. Krammer, M. Durst, S. Suhai, and W.G. Rowekamp Human papillomavirus type 16 DNA sequence Virology 145 1 1985 181 185
3. H. zur Hausen Papillomavirus infections - a major cause of human cancers Biochim Biophys Acta 1288 2 1996 F55 F78
4. R. Kirnbauer Papillomavirus-like particles for serology and vaccine development Intervirology 39 1-2 1996 54 61
5. R. Kirnbauer, F. Booy, N. Cheng, D.R. Lowy, and J.T. Schiller Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic Proc Natl Acad Sci USA 89 24 1992 12180 12184
6. R. Kirnbauer, L.M. Chandrachud, and B.W. O'Neil Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization Virology 219 1 1996 37 44
7. R. Kirnbauer, J. Taub, and H. Greenstone Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles J Virol 67 12 1993 6929 6936
8. J. Zhou, J. Doorbar, X.Y. Sun, L.V. Crawford, C.S. McLean, and I.H. Frazer Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein Virology 185 2 1991 625 632
9. C.D. Harro, Y.Y. Pang, and R.B. Roden Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine J Natl Cancer Inst 93 4 2001 284 292
10. K.H. Fife, C.M. Wheeler, and L.A. Koutsky Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women Vaccine 22 21-22 2004 2943 2952
11. D.R. Brown, K.H. Fife, and C.M. Wheeler Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine Vaccine 22 21-22 2004 2936 2942
12. L.A. Koutsky, K.A. Ault, and C.M. Wheeler A controlled trial of a human papillomavirus type 16 vaccine N Engl J Med 347 21 2002 1645 1651
13. D.M. Harper, E.L. Franco, and C. Wheeler Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 9447 2004 1757 1765
14. G. Meneguzzi, C. Cerni, M.P. Kieny, and R. Lathe Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7 Virology 181 1 1991 62 69
15. L.P. Chen, E.K. Thomas, S.L. Hu, I. Hellstrom, and K.E. Hellstrom Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen Proc Natl Acad Sci USA 88 1 1991 110 114
16. H.L. Greenstone, J.D. Nieland, and K.E. de Visser Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model Proc Natl Acad Sci USA 95 4 1998 1800 1805
17. I. Jochmus, K. Schafer, S. Faath, M. Müller, and L. Gissmann Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine Arch Med Res 30 4 1999 269 274
18. K. Schafer, M. Müller, and S. Faath Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection Int J Cancer 81 6 1999 881 888
19. A.M. Kaufmann, J. Nieland, and M. Schinz HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination Int J Cancer 92 2 2001 285 293
20. I. Jochmus, W. Osen, and A. Altmann Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide J Gen Virol 78 Pt 7 1997 1689 1695
21. M. Müller, J. Zhou, and T.D. Reed Chimeric papillomavirus-like particles Virology 234 1 1997 93 111
22. D.M. Da Silva, J.T. Schiller, and W.M. Kast Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines Vaccine 21 23 2003 3219 3227
23. D.C. Tang, M. DeVit, and S.A. Johnston Genetic immunization is a simple method for eliciting an immune response Nature 356 6365 1992 152 154
24. J.A. Wolff, R.W. Malone, and P. Williams Direct gene transfer into mouse muscle in vivo Science 247 4949 (Pt 1) 1990 1465 1468
25. H.L. Robinson, L.A. Hunt, and R.G. Webster Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA Vaccine 11 9 1993 957 960
26. J.B. Ulmer, J.J. Donnelly, and S.E. Parker Heterologous protection against influenza by injection of DNA encoding a viral protein Science 259 5102 1993 1745 1749
27. J.J. Donnelly, J.B. Ulmer, J.W. Shiver, and M.A. Liu DNA vaccines Annu Rev Immunol 15 1997 617 648
28. H. Herweijer, and J.A. Wolff Progress and prospects: naked DNA gene transfer and therapy Gene Ther 10 6 2003 453 458
29. B.J. Ledwith, S. Manam, and P.J. Troilo Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice Intervirology 43 4-6 2000 258 272
30. T. Martin, S.E. Parker, and R. Hedstrom Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection Hum Gene Ther 10 5 1999 759 768
31. D.L. Doolan, R.C. Hedstrom, and M.J. Gardner DNA vaccination as an approach to malaria control: current status and strategies Curr Topics Microbiol Immunol 226 1998 37 56
32. K.E. Ugen, S.B. Nyland, and J.D. Boyer DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans Vaccine 16 19 1998 1818 1821
33. K. Van Herck, P. Van Damme, M. Lievens, and M. Stoffel Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course J Med Virol 72 2 2004 194 196
34. K. Van Herck, P. Van Damme, S. Thoelen, and A. Meheus Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results Vaccine 16 20 1998 1933 1935
35. H.C. Ertl Rabies DNA vaccines for protection and therapeutic treatment Expert Opin Biol Ther 3 4 2003 639 644
36. J.B. Ulmer Influenza DNA vaccines Vaccine 20 Suppl. 2 2002 S74 S76
37. F.D. Cui, H. Asada, and T. Kishida Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice Gene Ther 10 25 2003 2059 2066
38. N. Michel, W. Osen, L. Gissmann, T.N. Schumacher, H. Zentgraf, and M. Müller Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination Virology 294 1 2002 47 59
39. M. Smahel, E. Sobotkova, and V. Vonka DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes and the activated ras oncogene Oncol Rep 6 1 1999 211 215
40. A.P. Wlazlo, H. Deng, W. Giles-Davis, and H.C. Ertl DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins Cancer Gene Ther 11 6 2004 457 464
41. N.R. Chu, H.B. Wu, T. Wu, L.J. Boux, M.I. Siegel, and L.A. Mizzen Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7 Clin Exp Immunol 121 2 2000 216 225
42. C. Leder, J.A. Kleinschmidt, C. Wiethe, and M. Müller Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes J Virol 75 19 2001 9201 9209
43. C.A. Chen, and H. Okayama Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA Biotechniques 6 7 1988 632 638
44. W. Osen, T. Peiler, and P. Ohlschlager A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity Vaccine 19 30 2001 4276 4286
45. N.D. Christensen, J.W. Kreider, N.M. Cladel, S.D. Patrick, and P.A. Welsh Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11 J Virol 64 11 1990 5678 5681
46. A. Wistuba, S. Weger, A. Kern, and J.A. Kleinschmidt Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins J Virol 69 9 1995 5311 5319
47. C.S. McLean, M.J. Churcher, and J. Meinke Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus J Clin Pathol 43 6 1990 488 492
48. Y. Ishii, K. Tanaka, and T. Kanda Mutational analysis of human papillomavirus type 16 major capsid protein L1: the cysteines affecting the intermolecular bonding and structure of L1-capsids Virology 308 1 2003 128 136
49. J.A. Wolff, J.J. Ludtke, G. Acsadi, P. Williams, and A. Jani Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle Hum Mol Genet 1 6 1992 363 369
50. S. Gurunathan, D.M. Klinman, and R.A. Seder DNA vaccines: immunology, application, and optimization* Annu Rev Immunol 18 2000 927 974
51. C. Balmelli, R. Roden, A. Potts, J. Schiller, P. De Grandi, and D. Nardelli-Haefliger Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions J Virol 72 10 1998 8220 8229
52. D. Baud, F. Ponci, M. Bobst, P. De Grandi, and D. Nardelli-Haefliger Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1 J Virol 78 23 2004 12901 12909
53. D. Nardelli-Haefliger, R.B. Roden, and J. Benyacoub Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice Infect Immun 65 8 1997 3328 3336
54. P. Ohlschlager, W. Osen, and K. Dell Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice J Virol 77 8 2003 4635 4645
55. L. Gissmann, W. Osen, M. Müller, and I. Jochmus Therapeutic vaccines for human papillomaviruses Intervirology 44 2-3 2001 167 175
56. J.S. Boyle, C. Koniaras, and A.M. Lew Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization Int Immunol 9 12 1997 1897 1906